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1. INTRODUCTION 
Pharmaceutical analysis is a branch of practical chemistry that involves a series of 
process for identification, determination, quantification and purification of a substance, 
separation of the components of a solution or mixture, or determination 
of structure of chemical compounds. The substance may be a single compound or 
a mixture of compounds and it may be in any of the dosage form. The substance used as 
pharmaceuticals are animals, plants, micro organisms, minerals and 
various synthetic products. 
The sample to be analysed is called as analyse and on the basis of size of sample, 
they can be classified as macro (0.1 g or more), semi micro (0.01 g to 0.1 g), micro 
(0.001 g to 0.01 g), sub micro (0.0001 g to 0.001 g), ultra micro (below 10-4 g), trace 
analysis (100 to 10000 ppm). Among all, the semi micro analysis is widely used. 
1.1. Analytical chemistry 
Types 
There are main two types of chemical analysis. 
1. Qualitative (identification) 
2. Quantitative (estimation) 
1. Qualitative analysis is performed to establish composition of natural/synthetic 
substances.  These tests are performed to indicate whether the substance or compound is 
present in the sample or not. Various qualitative tests are detection of evolved gas, 
formation of precipitates, limit tests, colour change reactions, melting point and boiling 
point test etc. 
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2. Quantitative analytical techniques are mainly used to quantify any compound or 
substance in the sample. These techniques are based in 
(a) The quantitative performance of suitable chemical reaction and either measuring the 
amount of reagent added to complete the reaction or measuring the amount of reaction 
product obtained. (b) The characteristic movement of a substance through a defined 
medium under controlled conditions. 
(c) Electrical measurement. 
(d) Measurement of some spectrophotometric properties of the compound. 
1.2. U.V SPECTROSCOPY 
A UV-vis spectrometer is simply a device that detects how much light is absorbed 
(blocked). First, a reading on a detector measures how much light reaches the detector 
without a sample present (before the sample in placed between the light source and 
detector). Then, when the sample in placed in the light path, if molecules (or atoms) 
absorb light, the detector "sees" a reduction in light reaching it. We call this reduction 
absorbance. 
The instrument used in ultraviolet-visible spectroscopy is called a 
UV/Vis spectrophotometer. It measures the intensity of light passing through a sample 
(I), and compares it to the intensity of light before it passes through the sample (Io). The 
ratio I / Io is called the transmittance, and is usually expressed as a percentage (%T). 
The absorbance, A, is based on the transmittance: 
A = − log (%T / 100%) 
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Many molecules absorb ultraviolet or visible light. The absorbance of a solution 
increases as attenuation of the beam increases. Absorbance is directly proportional to the 
path length, b, and the concentration, c, of the absorbing species. Beer's Law states that 
A = εbc, 
 where ε is a constant of proportionality, called the absorbtivity. 
Different molecules absorb radiation of different wavelengths. An absorption 
spectrum will show a number of absorption bands corresponding to structural groups 
within the molecule. For example, the absorption that is observed in the UV region for 
the carbonyl group in acetone is of the same wavelength as the absorption from the 
carbonyl group in diethyl ketone. 
Electronic transitions 
The absorption of UV or visible radiation corresponds to the excitation of outer 
electrons. There are three types of electronic transition which can be considered; 
1. Transitions involving σ, π and n electrons 
2. Transitions involving charge-transfer electrons 
3. Transitions involving d and f electrons  
When an atom or molecule absorbs energy, electrons are promoted from their 
ground state to an excited state. In a molecule, the atoms can rotate and vibrate with 
respect to each other. These vibrations and rotations also have discrete energy levels, 
which can be considered as being packed on top of each electronic level. 
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Absorbing species containing σ, π and n electrons 
Absorption of ultraviolet and visible radiation in organic molecules is restricted to 
certain functional groups (chromophores) that contain valence electrons of low excitation 
energy. The spectrum of a molecule containing these chromophores is complex. This is 
because the superposition of rotational and vibrational transitions on the electronic 
transitions gives a combination of overlapping lines. This appears as a continuous 
absorption band. 
Possible electronic transitions of σ, π and n electrons are; 
 
 
5 
 
Common solvents and cutoffs: 
 Acetonitrile - 190 
 Chloroform - 240 
 Cyclohexane - 195  
 1, 4-Dioxane - 215 
 95% Ethanol - 205 
 N-Hexane - 201 
 Methanol - 205 
 Isooctane - 195 
 Water  - 190 
Modern UV – Vis spectrophotometer  
 
The assay of an absorbing substance can be carried out by using 
a) Standard absorbtivity value. 
b) Use of calibration graph. 
c) Single point standardization. 
a) Standard absorptivity value: 
This procedure is adopted by official compendia for the stable substance that have 
reasonably broad absorption bands and which are practically unaffected by variation 
of instrumental parameters. The use of standard A (1%, 1cm) value avoids the need to 
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prepare a standard solution of the reference substance in order to determine its 
absorptivity. 
b) Use of calibration graph: 
 In this procedure, the absorbance of a number (typically 4-6) of standard solution 
of the reference substance at concentrations encompassing sample concentration is 
measured and a calibration graph is constructed. The concentration of the analyte in 
the sample solution is read from the graph as a concentration corresponding to 
absorbance of the solution. 
c) Single point standardization 
This procedure involves the measurement of the absorbance of a sample solution 
and of a standard solution of the reference substance. The standard and sample 
solution are prepared in a similar manner, ideally the concentration of standard 
solution should be close to that sample solution. The concentration of the substance in 
the sample is calculated by using 
 Ctest  =  
Atest   x Cstandard
Astandard
 
Where Ctest and Cstandard are the concentrations in the sample and standard 
solutions and Atest and Astandard are the absorbance of sample and standard solutions 
respectively.  
Important characteristics of spectrophotometric methods include, 
 High sensitivities 
 Moderate to high selectivity 
 Good accuracy 
 Wide applicability to both organic and inorganic systems. 
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 Easy and convenience of data acquisition. 
The use of UV and visible spectrophotometer for quantitative analysis employs 
the method of comparing the absorbance of standards and samples at a selected 
wavelength. The analysis of mixtures of two or more components is facilitated by activity 
of absorbance. Other applications include measurement of absorption of complexes to 
establish their composition. All chromogenic compounds are not suitable for quantitative 
measurements, i.e. the choice of the system and procedure depends largely on the 
chemistry of the species to be determined. 
Points to be considered in the selection of procedure include: 
 Stability of absorbance with respect to time, variation of pH, ionic strength and 
temperature. 
 Degree of selectivity of complexing agent includes the effect of other species 
likely to be present. 
 Conformity to the Beer-Lambert’s Law and plot calibration data for the range of 
concentration measured. 
In multi-component formulations, the presence of two or more drugs in a 
formulation give rise to interference components which mutually interfere with each 
other in their estimation. For the simultaneous estimation of drugs in such formulations 
many techniques have been applied. 
They are 
1) Simultaneous equation method 
2) Area under curve method 
3) Absorbance ratio method 
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4) Derivative spectroscopy method. 
5) Chemical Derivatization Methods. 
6) Multi-component mode of analysis. 
SIMULTANEOUS EQUATION METHOD 
If a sample contains two absorbing drugs (X and Y) each of which absorbs at the 
max of the other. It may be possible to determine the quantity of both drugs by the 
technique of simultaneous equation (or) Vierodt’s method. 
Criteria for obtaining maximum precision, based upon absorbance ratios have 
been suggested that place limits on the relative concentrations of the component of the 
mixture. 
A2 A1 
ax2 ax1 
         and          
ay2 ay1 
A2 A1 
     
Where, ax1, ax2 = Absorptivities of X at 1 and 2 
  ay1, ay2 = Absorptivities of X at 1 and 2 
A1, A2 = Absorbance of the diluted sample at 1 and 2. 
The ratio should lie outside the range of 0.1 – 2.0 for the precise determination of 
(Y and X) two drugs respectively. 
These criteria are satisfactory only when the max of the two components is 
reasonably dissimilar. The additional criteria includes that two components do not 
interact chemically, there by negating the initial assumption that the total absorbance is 
the sum of the individual absorbance 
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AREA UNDER THE CURVE METHOD (Telekone et al., 2010) 
            The area under curve method is applicable where there is no sharp peak or when 
broad spectra are obtained. It involves the calculation of integrated value of absorbance 
with respect to the wavelength between the two selected wavelengths λ1 and λ2. Area 
calculation processing item calculates the area bound by the curve and the horizontal 
axis. The horizontal axis is selected by entering the wavelength range over which area 
has to be calculated. This wavelength area is selected on the basis of repeated observation 
so as to get the linearity between area under curve and concentration. In combination 
drugs λ1 and λ2 denotes the wavelength ranges of the components. The integrated value of 
absorbance in the wavelength ranges of both the drugs are substituted in the simultaneous 
equation to get the concentration of the drugs. 
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DERIVATIVE SPECTROPHOTOMETRIC METHOD 
This method involves the conversion of normal spectrum to its first, second or 
higher derivative spectrum. The transformations that occur in the derivative spectra are 
understood by reference to a Gaussian band which represents an ideal absorption band. 
In this technique spectra are obtained by plotting the first or higher derivation of 
absorbance or transmittance with respect to wavelength versus wavelength. Often these 
plots reverse spectral details, with respect to wavelength versus wavelength. Often these 
plots reverse spectral details, which is lost in an ordinary spectrum. In addition 
concentration measurements of an analyte in the presence of their interference can 
sometimes be made easily or more accurately. 
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A first-order derivative spectrum is a plot of the gradient of the absorption curve (rate of 
change of the absorbance with wavelength, dA/dλ) against wavelength.  
     A second-order derivative spectrum is a plot of the curvature of the absorption 
spectrum against wavelength (d
2
A/dλ2). The second derivative at any wavelength λ is 
related to concentration by the following equations: 
 
For quantitative measurements, the amplitude is the distance between the adjacent 
maxima and minima is usually measured. 
Enhanced resolution, band width discrimination are the advantages of derivative 
spectrophotometry that permit the selective discrimination of certain absorbing 
substances in samples in which non specific interferences may prohibit the application of 
simple spectrophotometric methods. 
1.3 CHROMATOGRAPHY 
 Modern pharmaceutical formulations are complex mixtures including’ in addition 
to one or more therapeutically active ingredients, a number of inert materials such as 
diluents, disintegrants, colours and flavours. In order to ensure quality and stability of the 
final product, the pharmaceutical analyst must be able to separate the mixtures into 
individual components prior to quantitative analysis. 
Amongst the most powerful techniques available to the analyst for the separation 
of these mixtures are group of highly efficient methods collectively called 
chromatography. 
It is a group of technique for the separation of compounds of mixture that depends 
on the affinities of the solutes between two immiscible phases. One of the phases is 
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affixed bed of large surface area, while the other is a fluid which moves through the 
surface of the fixed phase. The fixed phase is called stationary phase, and the other is 
termed as the mobile phase.  
Depending on the type of chromatography employed, the mobile phase may be a 
pure liquid or a mixture of solutions (Eg. Buffer) or it may be gas (pure or homogenous 
mixture).  
Chromatographic methods can be classified according to the nature of the 
stationary and mobile phases.  
DEVELOPMENT OF THE REVERSE PHASE HPLC METHOD 
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VALIDATION (Sethi P.D., 2001) 
Validation of an analytical method is the process by which it is estimated, by 
laboratory studies, that the performance characteristics of the method meet the 
requirements for the intended analytical applications. 
REASONS FOR VALIDATION 
1. Enables scientists to communicate scientifically and effectively on technical matters. 
2. Setting standards of evaluation procedures for checking complaints and taking 
remedial measures. 
3. Retrospective validation is useful for trend comparison of results compliance to 
cGMP/GLP. 
4. Closer interaction with pharmacopoeia harmonization particularly in respect of 
impurities determination and their limits.  
5. For taking appropriate action in case of non – compliance. 
6. To provide high degree of confidence that the same level of quality is consistently 
built into each unit of finished product from batch to batch.  
7.  Economic: The consistency and reliability of validated analytical procedure is to 
produce a quality product with all the quality attributes, thus providing indirect cost 
saving from reduced testing or re testing and elimination of product rejection. 
As quality control process is not static, some form of validation / Verification 
should continue till the validated process is in use. 
 
 
 
13 
 
Summary of validation procedure  
Type of validation  Test for  
Specificity  
Accuracy  
Sensitivity  
Precision  
Personnel  
Equipment  
Service  
Interference  
Recovery ; linearity  
Limit of detection ; Limit of quantification 
Repeatability ; Reproducibility ; Ruggedness  
Qualifications ; Experience ; responsibility ; proficiency 
Specifications,  vendor, calibration, maintenance  
Sanitation, water, Waste disposal   
 
1.4. PARAMETERS USED FOR ASSAY VALIDATION (ICH Guidelines) 
Typical analytical characteristics used in method validation are  
Specificity  
Specificity is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present. Lack of specificity of an individual 
analytical procedure may be compensated by other supporting analytical procedures. 
Accuracy  
 The accuracy of an analytical procedure expresses the closeness of agreement 
between the value which is accepted either as a conventional true value or an accepted 
reference value and the value found. 
Precision  
 The precision of an analytical procedure expresses the closeness of agreement 
between a series of measurements obtained from multiple sampling of the same 
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homogenous sample under the prescribed conditions. Precision of an analytical procedure 
is usually expressed as the variance, standard deviation or coefficient of variation of a 
series of measurements.  
Repeatability  
         Express the precision under same operating conditions over a short interval of time. 
Repeatability is also termed as intra-assay precision.  
Linearity  
 Linearity of an analytical procedure is its ability (within a given range) to obtain 
test results which are directly proportional to the concentration (amount) of analyte in the 
sample. 
Range  
 Range of an analytical procedure is the interval between the upper and lower 
concentration (amount) of analyte in the sample (including these concentrations) for 
which it has been demonstrated that the analytical procedure has a suitable level of 
precision, accuracy and linearity.  
Detection limit  
 The detection limit of an individual analytical procedure is the lowest amount of 
analyte in a sample which can be detected but not necessarily quantitated as an exact 
value. 
 Based on the standard deviation of the response and the slope, the detection limit 
(DL) may be expressed as 
 DL =  
3.3 σ
S
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Where, 
σ = standard deviation of the response 
S = slope of the calibration curve (of the analyte) 
Quantification limit  
The quantification limit of an analytical procedure is the lowest amount of analyte 
in a sample which can be quantitatively determined with suitable precision, accuracy and 
reliability by the proposed method. 
 Based on the standard deviation of the response and the slope, quantitation limit 
may be expressed as  
QL =  
10 σ
S
 
Where, 
σ = standard deviation of the response  
S = slope of the calibration curve (of the analyte) 
1.5. System suitability parameters 
 
System suitability is an integral part of many analytical procedures. The tests are 
based on the concept that the equipment, electronics, analytical operations and samples to 
be analyzed constitute an integral system that can be evaluated as such. 
The system suitability testing parameters established for the liquid 
chromatographic procedure are: 
Retention time (Rt)  
This is the time of emergence of the maximum of a component after injection. 
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Symmetry factor (or) tailing factor (T)  
T =  
W0.05
2f
 
The assessment of peak shape is in terms of symmetry factor. 
Number of theoretical plates (N) 
𝑁 = 5.54   
𝑡
𝑊ℎ
2
 
 
2
 
 The assessment of performance of efficient of a column is in terms of the number 
of theoretical plates.  
Resolution 
2(𝑡2 − 𝑡1 )
𝑊2 +  𝑊1
 
1.6. Pharmaceutical Statistics 
Statistics consist of a set of methods and rules for organizing and interpreting 
observations. 
The precision or reproducibility of the analytical method was determined by 
repeating the analysis six times and the following statistical parameters were calculated. 
The Formulas are 
 Standard Deviation =  
  x – x  2
𝑛 − 1
 
R. S. D (%) =  
S. D
 x 
 X 100 
S. E =  
S. D
 n
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Where   = Sum of observations 
x = Mean or arithmetic average (x / n) 
x = Individual observed value 
x – x = Deviation of a value from the mean 
n = Number of observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LITERATURE 
REVIEW 
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2. LITERATURE REVIEW 
2.1 DRUG PROFILE  
2.1.1 CELECOXIB (The Merck Index 2006, www.wikipedia.com) 
Molecular structure  
N
N
CF3
S
O
O
NH2
CH3  
Chemical name 
 4[5(4-methylphenyl)-3-[trifluoromethyl]pyrazol-1yl-benzene sulfonamide 
Molecular formula 
C17H14F3H3O2S 
Molecular weight   
381.373 gm/ mol  
Category  
Celecoxib is an NSAID, a selective inhibitor of cyclo-oxygenase-2 (COX-2). 
Celecoxib is used in the treatment of rheumatoid arthritis and osteoarthritis. 
Primary characteristics 
It is of synthetic origin and belongs to NSAID. 
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Identification 
i) Melting Point 
Standard Value Observed Value* 
     158-162° C 161.16° C 
 
  *Average of six determination 
Pharmacokinetics 
        Volume of distribution is found to be 500 l/ kg and plasma protein binding is 97%. 
Renal Excretion accounts for < 1% and plasma half life is ~97. 
Indications 
Celecoxib is primarily indicated in conditions like osteoarthritis, rheumatoid 
arthritis, and can also be given in adjunctive therapy as an alternative drug of choice 
in dysmenorrhoea, pain, and toothache. 
Side effects 
The severe or irreversible adverse effects of Celecoxib, which give rise to further 
complications, include GI bleeding, Rhinitis, Myalgia, Urinary tract infection, 
Bronchitis, Pharyngitis. The symptomatic adverse reactions produced by Celecoxib are 
more or less tolerable and if they become severe, they can be treated symptomatically, 
these include Flatulencce, Dizziness, Headache, Vomiting, Diarrhoea, Constipation, 
Insomnia, Abdominal pain, Rashes, Pruritus, Dyspepsia, Cough. 
Warning and precautions 
It is classified as pregnancy category C, and should be used with caution during 
pregnancy only if clearly needed. Avoid use in case of hypersensitivity to Celecoxib or 
any component, sulphonamides, aspirin or other non steroidal anti-inflammatory drugs. 
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Storage 
Capsules: Store in a well closed container, Between 20°C-25°C. Protect from Moisture 
and Heat. 
2.1.2 DIACEREIN (Indian Pharmacopeia, 2010 and The Merck Index, 2006) 
Molecular structure  
O O
O
COOH
O
O
CH3
O
CH3
 
Chemical name 
 9,10-dihydro-4,5-dihydroxy-9,10-dioxo-2-anthranoic acid diacetate 
Molecular formula 
C19H12O8 
Molecular weight   
368.294 
Category 
Antirheumatic, it is used in the treatment of osteoarthritis and chronic 
inflammatory arthritis.  
Description 
  Fine yellow power         
Solubility 
  Freely soluble in dimethyl sulfoxide (DMSO) 
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Identification 
i) Melting Point 
Standard Value Observed Value* 
217-218° C 217.83° C 
 
  *Average of six determination 
Storage 
        Store protected from light. 
Absorption, Distribution, Metabolism and Elimination 
Absorption: 
   Oral bioavailability of the diacerein is 35% to 56% concurrent intake of food 
delays the time to peak concentration from 2.4 hours to 5.2 hours, but it is associated with 
a 25% increase in absorption. Therefore, diacerein is best given with food. 
Distribution: 
  The total protein binding of rhein, a metabolite is about 99% to plasma albumin 
and γ-immunoglobulins. It achieves synoviral fluid concentration of 0.3 to 3.0 mg/ L 
Metabolisum: 
 Diacerein is metabolised completely (100%) in liver following oral dosing prior 
to entering systemic circulation. The cell localization of this deacetylation has not been 
definitively identified, but plasma can be ruled out. Major active metabolites include 
rhein sulfate with half life being 7 to 8 hours. 
Elimination: 
Diacerein is excreted in urine in the form of its metabolites (35-60%), with approximately 
20% as free rhein and 80% as conjugates of rhein. 
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Contra indication:  
a) Hypersensitivity to diacerein of any components of the product. 
b) Combined use of diacerein with laxatives is contraindicated. 
Side effects: 
 Nausea, dry mouth, constipation, diarrhoea, vomiting, decrease appetite, 
dizziness, headache, increased sweating, hot flushes and anxiety. 
Drug interactions: 
 Diacerein given with food shown increase in absorption by 25% the drug 
combinely used with laxatives may cause interactions, hence contraindicated. 
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2.2. LITERATURE REVIEW 
2.2.1 REPORTED METHOD FOR CELECOXIB 
1. Jayasagar G., et al., (2002) reported validated HPLC method for determination of 
Celecoxib in human serum and it applications in pharmacokinetic study. This 
chromatography achieved on C18, Wakosil column with a mixture of 10 M Potassium 
dihydrogen ortho phosphate (pH 3.2) and acetonitrile (50:50 v/v) at 250 nm. 
2. Saha RN., et al., (2002) reported determination of Celecoxib in pharmaceutical 
formulations using UV spectroscopy and liquid chromatography. The linear 
regression equations are obtained by least square regression method were ABS= 
4.949 x 10 (-2). Conc. (in ng/ ml) +1.110 x 10(-2) for the UV method and Area under 
the curve=5.340 x 10(1). Conc. (in ng/ ml) +3.144 x 10(2) for the LC method. 
3. Neelamseedher et al., (2003) reported spectrophotometric method for estimation of 
some COX-2 inhibitors in pure form in pharmaceutical formulations. UV 
spectrophotometric method for estimation of Celecoxib, Rofecoxib, Meloxicam and 
Nimusulide in pure form of pharmaceutical formulations solvents employed for 
method 0.1 N sodium hydroxide. 
4. Chandran S., et al., (2006) reported rapid and sensitive spectrofluorimetric method 
for estimation of Celecoxib and Flurbiprofen. The excitation and emission 
wavelengths were found to be 256 nm and 403 nm respectively for Celecoxib in 
water and 250 nm and 314 nm respectively for flurbiprofen in 1:1 mixture of 
methanol and 0.1 N H2SO4. The linear regression equation obtained by least square 
regression method for fluorescence intensities (F5) and concentration in mg/ mL. 
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5. Murthy TEGK., et al., (2006) reported reverse phase HPLC determination of 
Celecoxib in dosage forms using ODS column in mixture of 0.2 % v/v of glacial 
acetic acid and acetonitrile (32:68 v/v) at 260 nm.  
6. Archana Roy., et al., (2008) reported “Development of rapid UV spectrophotometric 
methods for estimation of Celecoxib and Acyclovir in formulations”. The λ 
determination for Celecoxib was determined in 0.1 N HCl with 1% w/v, SLS at 255 
nm. And that of acyclovir in 0.1 N HCl at 257 nm. 
2.2.2. REPORTED METHOD FOR DIACEREIN 
1. Giannellini V., et al., (2005) reported “A validated HPLC stability-indicating method 
for determination of Diacerein in bulk drug substance”. This chromatography method 
was achieved on a RP18 (End capped coloum) utilizing 0.1 M phosphoric acid and 
methanol (40:60 v/v) at 254 nm. 
2. Keddal G. Lalitha., et al., (2009) reported a simple HPLC method for quantitation of 
in tablet dosage form. This chromatographic method was achieved on ZorbaxCN 
column with a mixture of ammonium acetate buffer (pH adjusted to 3.5): Acetonitrile 
(53:47) at 254 nm. 
3. Janhavi Rao., et al., (2009) reported “Stability-Indicating high performance liquid 
chromatographic method for the determination of Diacerein in capsules”. This 
chromatographic separation was achieved on ODS C18 column with mobile phase 
mixture of Acetonitrile: phosphate buffer (60: 40 % v/v) pH4 adj with phosphoric 
acid at 254 nm. 
4. Sarika NArade., et al., (2010) reported “Development and Validation of UV 
Spectrophotometric method for determination of Diacerein capsules”. Diacerein 
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shows maximum absorbance at 258.5 nm with molar absorbtivity of                    
4.2258 x 10
4
 l/mol/cm.  
5. Sekar V., et al., (2010) reported “Development and validation of RP-HPLC method 
for simultaneous estimation of Diacerein and Aceclofenac in dosage form. This 
chromatographic method was achieved on Phenomenex Luna C18 5µ, 250 mm x 4.6 
mm column, using dipotassium hydrogen phosphate buffer of pH 4.5 acetonitrile and 
methanol in ratio of 40:40:20 at 260 nm. 
6. Kannappan N., et al., (2010) reported “Analytical method development and 
Validation of Diacerein tablets by RP-HPLC”. This chromatographic method was 
achieved on Zorbax CN, the mobile phases were comprised of Acetonitrile and 
Buffer pH-3.5. 
7. Siva Kumar R., et al., (2010) “Visible spectrophotometric estimation of Diacerein in 
bulk and formulation form”.  Method A is based on the reaction of Diacerein with 
Folin-Ciocalteu reagent, in the presence of 0.5 N sodium hydroxide solution, giving a 
pink-colored chromogen, which shows maximum absorbance at 512 nm against 
reagent blank while method B is based on the oxidation of Diacerein with potassium 
permanganate in an alkaline medium giving a pink-colored chromogen, which shows 
maximum absorption at 497.5 nm. 
8. Sreejith K.R., et al., (2010) “Novel Spectrophotometric Methods for Estimation of 
Diacerein from Formulations”. Method I was developed using solvent pyridine with 
minimum processing steps which showed maximum absorbance at 435 nm. In 
Method II a spectrophotometric method was developed using 0.1N sodium hydroxide 
which showed λmax at 503 nm. 
  
PLAN OF 
WORK 
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3. AIM AND PLAN OF WORK 
 
 The combination dosage form selected for the present study contains 
CELECOXIB and DIACEREIN in solid oral dosage forms, recently this combination of 
the drugs introduced into market. 
In the view of the literature cited for the quantification of CELECOXIB and 
DIACEREIN it was felt that a rapid and accurate method for estimation of CELECOXIB 
and DIACEREIN individually and in combination with other drugs was available, but no 
method is available in combined dosage form. The present work is aimed to develop a 
method for estimation of the drugs in combined capsule dosage form.  
For UV method, 
1. find the drugs solubility in various solvents 
2. to determine maximum absorbance and overlaid 
3. determining the standard absorbance for all selected wavelength for each 
drugs 
4. development of simple, precise, accurate and sensitive 
 Simultaneous equations method 
 Area under curve method using (Simultaneous equation) 
 Derivative method, in the specified range 
5.  Validation of development as per ICH guidelines 
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 For RP-HPLC method, 
1. Selection of mobile phase for suitable for two drugs which proper 
resolution with possible short duration time 
2. While selecting mobile phase cost be consider to make this method for the 
route analysis 
3. Development of chromatogram with various concentration for each drug 
to determine range of concentrations 
4. Relating area of chromatogram with respect to concentration for 
individual drugs 
5. Development of chromatogram in formulation Validation of the developed 
method 
 
 
 
 
 
 
 
 
  
 
Materials 
& 
Methods 
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4. MATERIALS AND METHODS 
4.1 MATERIALS USED 
4.1.1 Drug samples used 
CELECOXIB and DIACERIEN were generoumacy gifted by Zydus Cadila 
Health Care Ltd, Ahmedabad. 
4.1.2 Formulation used 
        (OSTIGARD®100) containing 100mg Celecoxib and 50mg of Diacerein was gifted 
by Zydus synovial (A division of Cadila Health care Limited)    
4.1.3 Chemicals and Solvents used 
All the chemicals used were of analytical grade and HPLC grade procured from 
Qualigens, India Ltd.  The chemicals used for the study were, 
Methanol (HPLC grade) 
Acetonitrile (HPLC grade) 
Water (HPLC grade) 
Methanol (Analytical grade) and 
DMSO (Analytical grade) 
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4.1.4 Instruments Used 
Instruments employed for the study were, 
 SHIMADZU AUX - 220 Digital Balance 
 SHIMADZU – 1700 Double Beam - UV –Visiblspectrophotometer 
with pair of 10 mm matched quartz cell 
 Thermal scientific spectra HPLC 
 ELICO SL 159 Spectrophotometer 
 ELICO pH meter (Model LI - 120) 
 Melting point apparatus 
4.1.5 Instruments Specifications 
1) Shimadzu AX – 200 digital balance: (Shimadzu instruction manual) 
Specifications 
Weighing capacity 200 gms 
Minimum display 0.1 mg 
Standard deviation ≤ 0.1 mg 
Operation temperature range  5 to 40° C 
 
B) Shimadzu UV – Visible spectrophotometer: (Shimadzu instruction manual) 
Model : Shimadzu, UV-1700, pharmaspec; Cuvetts: 1 cm matched quartz cells 
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Specifications 
Light source 20 W halogen lamp, Deuterium lamp. Light source 
position automatic adjustment mechanism. 
Monochromator Aberration-correcting concave holographic grating 
Detector Silicon Photodiode 
Stray Light 0.04% or less (220 nm: NaI 10 g/ L) 
0.04% or less (340 nm: NaNo2 50 g/ L) 
Measurement wavelength 
range 
190-1100 nm 
Spectral Band Width 1 nm or less (190 to 900 nm) 
Wavelength Accuracy ± 0.5 nm automatic wavelength calibration mechanism 
Recording range Absorbance : -3.99~3.99 Abs 
Transmittance : -399~399% 
Photometric Accuracy ± 0.004 Abs (at 1.0 Abs), ±0.002 Abs (at 0.5 Abs) 
Operating  
Temperature/Humidity 
Temperature range : 15 to 35° C 
Humidity range : 35 to 80% (15 to below 30° C) 
          35 to 70% (30 to 35° C) 
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C)  INSTRUMENT SPECIFICATIONS FOR HPLC 
THERMO SCIENTIFIC SPECTRA HPLC SYSTEM  
COMPRISING THE FOLLOWING MODULES 
 
 
 
COMPRISING THE FOLLOWING MODULES 
                   PUMP                  P4000 
         AUTO SAMPLER                AS 3000 
          UV –VIS DETECTOR                UV 2000 
        VACUME DEGASSER                SCM 1000 
     SYSTEM CONTROLLER                  SN 4000 
          SAMPLE COOLER             UP TO 2- 4° C  
           SOFT WARE 
           CHROM QUEST 5.0 
 
 
4) Sonica ultra sonic cleaner- model 2200 MH 
5) ELICO – pH meter model L1610 
6) Micropipette 
7) Melting point apparatus - Guna enterprises Chennai  
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4.2 METHODS 
 
Methods employed for UV-spectroscopy 
In the present work an attempt was made to develop and validate a simple, precise 
and accurate method for the estimation of Celecoxib and Diacerein in pure and in 
combined tablet dosage form by UV spectrophotometry and RP-HPLC method. 
4.3 UV SPECTROPHOTOMETRIC METHODS 
4.3.1. Simultaneous Equation Method 
4.3.2. Area under curve method  
4.3.3. Derivative Spectrophotometric Method 
4.4. RP-HPLC 
4.3. UV SPECTROPHOTOMETRIC METHOD 
SELECTION OF SOLVENT 
 The solubility of drugs was determined in a variety of solvents as per Indian 
pharmacopoeia standards. Solubility was carried out in polar to non polar solvents. The 
common solvent was found to be 1mL of DMSO/methanol were chosen as solvent for 
Spectrophotometry, and it was selected on account of its ready availability, cost factor, 
and solubility for the analysis of Celecoxib and Diacerein for proposed method. 
Preparation of standard stock solution of Celecoxib 
 10 mg of Celecoxib  raw material was weighed accurately and transferred into 10 
mL volumetric flask and dissolved in 1 mL D.M.S.O and made up to the volume with 
methanol. This solution was observed to contain 1000 g/ mL. From this 2 mL volume of 
Celicoxib stock is transferred to 25 mL volumetric flask and made up to required volume 
with methanol to get con concentration of 80 µg/ mL. It is used as working standard. 
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Preparation of standard stock solution of Diacerein 
 10 mg of Diacerein raw material was weighed accurately and transferred into 10 
mL volumetric flask and dissolved in 1 mL DMSO and made up to the volume with 
methanol. This solution was observed to contain 1000 g/ mL.  From this 1 mL volume 
of stock solution is transferred to 25 mL volumetric flask and made up to required 
volume with methanol to get con concentration of 40 µg/ mL. It is used as working 
standard. 
Selection of wavelength 
The selection of wavelengths for the estimation Celecoxib and Diacerein suitable 
diluted stock solution contain 10 g/ mL of each and the solutions were scanned between 
200 – 400 nm by using methanol as blank. From the overlain spectra, by the observation 
of spectral characteristics of Celecoxib and Diacerein were selected for simultaneous 
estimation. The wavelengths selected were 236 nm and 269 nm. For Area under curve 
236-236 nm and 267-273 nm were selected as wave lengths form the overlaid spectrum. 
For Derivative spectrophotometric method, the zero order spectrum was derivatized to 
first order spectrum in that 294 nm was selected for estimation of Celecoxib, which is 
zero crossing for Diacerein and 245 nm was selected for estimation of Diacerein which is 
zero crossing point of Celecoxib 
LINEARITY AND CALIBRATION 
4.3.1 Simultaneous Equation method  
From the working stock solution of Celecoxib (80 µg/ mL), pipette out 0.5 to 2.5 
mL into a series of five 10 mL volumetric flask and made up to mark with methanol to 
get concentration range of 4 to 20 µg/ mL.  From the working stock solution of Diacerein 
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(40 µg/ mL), pipette out 0.5 to 2.5 mL into a series of five 10 mL volumetric flask and 
made up to mark with methanol to get concentration range of 2 to10 µg/ mL. 
The linearity was carried out individually for both the drugs and absorbances of 
these solutions were measured at 236 nm and 269 nm. 
4.3.2 FOR AREA UNDER CURVE METHOD 
From the working stock solution of Celicoxib (80 µg/ mL) and Diacerein          
(40 µg/ mL), pipette out 0.5 to 2.5 mL into a series of five 10 mL volumetric flasks 
separately and made up to mark with methanol to get concentration range of 4 to 20 µg/ 
mL for Celecoxib and 2 to 10 µg/ mL  for Diacerein . 
The linearity was carried out individually for both the drugs and area of these 
solutions was measured at 236-246 nm and 267-273 nm. 
4.3.3 FOR DERIVATIVE SPECTROPHOTOMETRIC METHOD 
The ΔA/Δλ values were measured in the first order derivative mode. Derivatised 
values were measured at 294 nm and 245 nm. The calibration curve for all the 
wavelengths were constructed by plotting ΔA/Δλ Vs concentration for first order 
derivative method. 
QUANTIFICATION IN FORMULATION 
Twenty Capsules were weighed and average weight of each capsule was found. 
The contents of the capsules were removed. The content of the drug equivalent to 25 mg 
of Diacerein was transferred to a 50 mL standard flask and the content of the flask was 
dissolved in DMSO and methanol by sonication for 15 minutes and made up to the 
volume and filtered through Whatmann filter paper (No.41). The solution was diluted to 
get a concentration of 10 µg/ mL in methanol.  
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Absorbance of the diluted sample solutions were measured at 236 nm and 269 nm 
for Simultaneous Equation Method,  area at 236-246 nm and 267-273 nm for area under 
curve method and  ΔA/Δλ 294 and 245 nm for first order derivative Spectrophotometric 
Method. 
Validation of developed method  
Linearity 
 A calibration curve was plotted between concentration and absorbance. Celecoxib 
was linear with the concentration range of 4 – 20 µg/ mL and Diacerein showed the 
linearity in the range of 2 – 10 µg/ mL at selected wavelengths for both the methods. 
RECOVERY STUDIES 
In order to ensure the accuracy of the proposed method, recovery studies were 
carried out. To 50 % of the pre-analyzed sample solution, a definite concentration of    
6.4, 8 and 9.6 µg/ mL standard solution of Celecoxib and 3.2, 4 and 4.8 µg/ mL standard 
solution of Diacerein were added and then its recovery was studied. The absorbance of 
resulting solutions was measured at their corresponding wavelengths and the percentage 
recovery was calculated. 
PRECISION 
Precision of the method was demonstrated by repeatability studies. Repeatability 
studies were done by consequently analyzing the sample solution for six times. Intraday 
and inter day precision were established by repeating the determination on the same day 
and on different days respectively.  
Ruggedness  
 Ruggedness of the method was confirmed by the analysis of formulation was 
done by the different analysts. The amount and % RSD were calculated. 
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LIMIT OF DETECTION AND LIMIT OF QUANTIFICATION 
The linearity studies were carried out for six times. The limit of detection and 
limit of quantification were calculated by using the average of slope and standard 
deviation of intercept. 
4.4 REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC 
METHOD 
Chromatographic method depends up on the nature of the sample, molecular 
weight and solubility. The drug selected for the present study was polar compound, hence 
it can be separated either by normal phase or reverse phase chromatography. Reverse 
phase chromatographic technique was selected for initial separations with the knowledge 
of properties of compound, LichroCART 250-4(Lichrospher 100) – RP 18e – (5 μm) 
column was chosen as stationary phase and various mixtures of methanol and water were 
considered as mobile phase. 
SELECTION OF MOBILE PHASE AND λmax 
Different mixtures of mobile phase with various ratios were selected and their 
chromatograms were recorded. From this methanol:water was selected as mobile phase, 
since these two drugs were eluted with sharp peak and with better resolution. Hence this 
mobile phase was used to optimize the chromatographic conditions. 
OPTIMIZED CHROMATOGRAPHIC CONDITIONS 
The following parameters were used for RP-HPLC analysis of Celecoxib and 
Diacerein. 
Mode of operation  –  Isocratic  
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Stationary phase  –  LichroCART 250-4(Lichrospher 100) – RP 18e – (5 μm)  
Column 
Mobile phase   –  Methanol: Water 
Ratio    –  85:15 
Detection wavelength –  252 nm 
Flow rate   –  1 mL/ min. 
Column Temperature  –  30°C 
Sample volume  –  20 µg/ mL 
Operating pressure  –  150 kgf 
PREPARATION OF THE STANDARD STOCK SOLUTION 
Weighed accurately 100 mg of Celecoxib and 50 mg of Diacerein , transferred 
into a 500 mL standard volumetric flask separately and dissolved with acetonitrile        
250 mL and the volume was made up to the mark with methanol. From the above 
solutions 5 mL were transferred to a 10 mL flask and diluted with methanol to get the 
concentration of 100 µg/ mL Celecoxib and 50 µg/ mL for Diacerein. 
LINEARITY AND CALIBRATION 
From the standard solution, pipette  0.7-1.3 mL into a series of seven 10 mL flask 
and made up to the mark with mobile phase to obtain the concentration range from 70-
130 µg/ mL for Celecoxib and 35-65 µg/ mL for Diacerein solution were injected and 
chromatogram was recorded. The calibration curve was plotted between concentration 
and peak area. 
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QUANTIFICATION OF CELECOXIB AND DIACEREIN 
Twenty Capsules were weighed and average weight of each capsule was found. 
The content of the capsules removed. The content of the drug equivalent to 100 mg of 
Celecoxib which also contains 50 mg of Diacerein was transferred to a 500 mL 
volumetric flask and   the content of flask was dissolved in 250 mL acetonitrile by 
sonication for 15 minutes and made up to the volume with methanol and filter through 
Whatmann filter paper (No. 41) and 5 mL was pipetted into a 10 mL volumetric flask and 
made up to the mark with methanol to produce 10 µg/ mL solutions. The peak area 
measurements were done by injecting sample (20 µg/ mL) six times and the amount of 
Celecoxib and Diacerein were calculated from their respective calibration curve. 
RECOVERY STUDIES 
To ensure the reliability of the method, recovery studies were carried out by 
mixing a known quantity of standard drug solution with the pre-analyzed sample 
formulation and the content were mixed and made up to the volume with mobile phase 
and pre-analyzed by the proposed method, the percentage recovery was calculated. 
LIMIT OF DETECTION AND LIMIT OF QUANTIFICATION 
The linearity studies were carried out for six times. The limit of detection and 
limit of quantification were calculated by using the average of slope and standard 
deviation of response. 
SYSTEM SUITABILITY STUDIES 
The system suitability studies were carried out as specified in I.P. the parameter 
like Column efficiency, Tailing factor, Asymmetric factor, and Theoretical plate number 
and were calculated. 
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5. RESULTS AND DISCUSSION 
 
            Estimation of multiple drug formulations have advantage that the methods are 
time consuming and usage of solvent is minimized. Three simple, rapid, precise and 
accurate spectrophotometric  methods  and  an  isocratic  RP – HPLC  method  were 
developed and validated for the  estimation  of  Celecoxib and  Diacerein  in  pure form 
and in combined capsule dosage form. The methods employed  
5.1 UV-SPECTROPHOTOMETRIC STUDIES 
            The identification of Celecoxib and Diacerein were confirmed by melting point 
analysis and IR spectral studies (Fig. 1 and 2) 
The solubility of Celecoxib and Diacerein were determined in a variety of 
solvents using Schefter and Higuchi method. 10 mg samples were taken in test tube and 
checked their solubility with variety of solvents as per IP and the profiles were shown in 
Table-1. 
The common solvent was found to be 1 mL of DMSO/methanol were chosen as 
solvent for Spectrophotometry, and it was selected on account of its ready availability, 
cost factor, and solubility for the analysis of Celecoxib and Diacerein for proposed 
method. The drugs were stable in DMSO/methanol up to two hours for Celecoxib and 
Diacerein respectively. 
Three simple, sensitive and precise UV methods namely, simultaneous equation 
method, area under curve and derivative spectrophotometric methods were selected for 
the determination of Celecoxib and Diacerein in pharmaceutical formulations. 
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The drugs were dissolved in methanol to produce 10 µg/ mL, they were scanned 
in the range of 200-400 nm and it shows constant λmax at 236 nm for Celecoxib and 269 
nm for Diacerein and overlaid spectra was made. This is shown in Fig-3, 4 and 5 
respectively. Stability of absorbance at their λmax was also checked. 
The linearity of Celecoxib and Diacerein was constructed in the range of 4-20 and 
2-10 µg/ mL and their calibration curves were shown in Fig. 6 to 13 respectively. A 
simple, accurate, rapid and precise first order derivative method was developed and 
validated. The common solvent used for estimation of Celecoxib and Diacerein was 
chosen as 1 mL DMSO and methanol. 
The sample solutions of 10 g/ mL of Celecoxib and Diacerein in 1 mL DMSO 
and methanol prepared individually and the solutions were scanned in UV region in the 
wavelength range from 200 to 400 nm by using methanol as blank. The zero order 
spectrums were derivatized into first order derivative spectrum. The overlaid first order 
derivative spectrum of Celecoxib and Diacerein was recorded as shown in Figure 14, 15 
and 16. From the spectrum, 294 nm and 245 nm were selected for the estimation of 
Celecoxib and Diacerein respectively without any interference. At 245 nm, Celecoxib has 
zero absorbance and at 294 nm, Diacerein has zero absorbance value. Hence these two 
wavelengths were selected for the analysis of Celecoxib and Diacerein, respectively.  
Different aliquots of Celecoxib and Diacerein were prepared in the concentration range of 
4 - 20 g/ mL and 2 – 10 g/ mL, respectively. The absorbances of these solutions were 
measured at 294 nm and 245 nm in the first order derivative spectrum for Celecoxib and 
Diacerein, respectively. The plotted graphs are shown in Figure 17 and 18 for Celecoxib 
and Diacerein, respectively. 
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The optical characteristics such as Beer’s law limit (4-20 and 2-10 µg/ mL), 
Molar extinction co-efficient, Sandell’s sensitivity, Correlation co-efficient, Slope and 
Intercept were calculated and are shown in Table- 2, 7 and 12 respectively. 
The limit of detection and the limit of quantification were determined from the 
linearity studies which was done 6 times and calculated by using slope and standard 
deviation of response (Intercept).  
The formulation OSTIGARD
®
 was selected for analysis. The amount present 
were determined by calculating the average of six replicate analysis and its percentage 
purity was found to be in the range of 98-101 % by the three methods. It is shown in 
Table- 3, 8 and 13 respectively. 
To evaluate the accuracy of the method, recovery studies were carried out, known 
amount of pure drug was added to the pre-analyzed solution containing formulation and 
the mixture was analyzed by the proposed methods, and their recoveries were calculated. 
The percentage recovery of Celecoxib and Diacerein in the formulation OSTIGARD
®
 
was found to be in the range of 98-102%. These values are shown in Table- 6, 11 and 16. 
Precision of the method was studied by making repeated analysis of the same 
sample and it was carried out three times in a day and for three days by two other 
analysts. The %RSD and standard deviation for inter-day and intra-day analysis was 
found to be less than 2 indicates the method is precise, which are shown in Table 4, 5, 10, 
11, 14 and 16 respectively. 
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5.2 RP-HPLC METHOD 
An effort was made to develop a simple, precise and accurate method for the 
method development and estimation of Celecoxib and Diacerein in bulk and in combined 
capsule dosage form by RP-HPLC method.  
SELECTION OF MOBILE PHASE 
Methanol was preferred because of its lower viscosity and high UV transparency. 
Methanol was selected due to its inexpensiveness. Methanol: Water in the ratio 85: 15 
was selected and this gave sharper peaks with good resolution and it was selected as 
mobile phase. The base line and individual chromatograms of Celecoxib and Diacerein 
were recorded shown in Fig 19, 20 and 21 respectively. The detection wavelength was 
measured by scanning the solution of Celecoxib and Diacerein in mobile phase, in UV 
spectrophotometry, overlaid spectra and the wavelength of maximum absorption was 
selected as 252 nm. The limit of detection and the limit of quantification were determined 
by using slope and standard deviation response. The system suitability parameters such as 
theoretical plate, Tailing factor, Asymmetric factor and Resolution were calculated and 
shown in Table-17, the parameters were found to be satisfactory as per guidelines. 
With the optimized chromatographic conditions, stock solutions of Celecoxib and 
Diacerein were prepared in Acetonitrile and methanol (1:1) and   prepared the mixture in 
the concentration range 70-130 µg/ mL of Celecoxib and 35-65 µg/ mL of Diacerein.    
20 μL of each solution was injected and records the chromatogram at 252 nm. The 
chromatogram were recorded and shown in Fig.22 to 28 
The calibration curve was plotted using concentration against peak area. The 
procedure was repeated for three times. The correlation coefficient was found to be above 
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0.9998 and 9996 for two drugs. The calibration graph of Celecoxib and Diacerein are 
shown in Fig.29 and 30 characteristics of Celecoxib and Diacerein shown in Table-18. 
The capsule dosage form OSTIGARD
®
 was selected for the analysis. The 
ostensible concentration 100 µg/ mL of Celecoxib and 50 µgm/mL
 
of Diacerein in the 
mobile phase were prepared. 20 μL of each solution was injected and chromatograms 
were recorded. The percentage purity was found to be 98.98 % Celecoxib and 99.77 % of 
Diacerein respectively. 
The precision of the method was confirmed by repeatability of formulation for 
nine times and the chromatograms are shown in Fig.31-39. The percentage of RSD was 
found to be 0.1257 and 0.0878 for Celecoxib and Diacerein respectively. The data is 
shown in Table-19.The accuracy of the method was performed by recovery studies to the 
pre - analyzed formulation, a known quantity of Celecoxib and Diacerein raw material 
solutions were added at different levels, injected the solutions. The chromatograms were 
recorded as shown in the Fig.40 - 42. The percentage recovery was found to in the range 
between Celecoxib 99.98% and 99.76% Diacerein. The percentage RSD was found to be 
0.305 and 0.387 for Celecoxib and Diacerein respectively. The low percentage of RSD 
values for recovery indicated that the method was found to be accurate. The values were 
given in the Table-20. The high percentage recovery revealed that no interference was 
produced due to the excipients used in formulation. Therefore developed method was 
found to be accurate. All the above parameters with the ease of operations ensure that the 
proposed methods could be applied for the routine analysis of Celecoxib and Diacerein 
pure form and in capsule dosage form. 
  
 
 
SUMMARY  
AND  
CONCLUSION 
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6. SUMMARY AND CONCLUSION 
Celecoxib is chemically 4[5(4-methylphenyl)-3-[trifluoromethyl] pyrazol-1yl-
benzene sulfonamide. It is a NSAID, a selective inhibitor of cyclo-oxygenase-2 (COX-2). 
Celecoxib is used in the treatment of rheumatoid arthritis and osteoarthritis. 
Diacerein is chemically 9, 10-dihydro-4, 5-dihydroxy-9, 10-dioxo-2-anthranoic 
acid diacetate. It is an anti rheumatic and used in the treatment of osteoarthritis and 
chronic inflammatory arthritis. 
Literature survey reveals that there is no analytical method reported for   
Simultaneous estimation of Celecoxib and Diacerein in pharmaceutical dosage form. 
So the present study aims to develop a newer, rapid, accurate and precise 
analytical method for the Simultaneous estimation of Celecoxib and Diacerein in the 
formulation of OSTIGARD®. 
The proposed analytical methods are simple, economical, rapid, sensitive, 
reproducible and accurate for the simultaneous estimation of Celecoxib and Diacerein. 
The methods adopted for studies were, 
1. UV- SPECTROPHOTOMETRIC METHOD  
1.1 Simultaneous equation method 
1.2 Area under curve 
1.3 Derivative spectrophotometric method 
2. RP-HPLC 
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The drug samples containing Celecoxib and Diacerein in combined capsule 
dosage forms were analyzed by UV-spectrophotometric method using 1 mL DMSO and 
methanol as a solvent and the contents of drug determined in each formulation was found 
to be satisfactory. 
UV-spectrophotometric method for the estimation of Celecoxib and Diacerein in 
combined capsule dosage form by 
Simultaneous equation method 
Area under the curve using simultaneous equation method and 
Derivative spectrophotometric method 
6.1 UV SPECTROPHOTOMETRIC METHODS 
Simultaneous equation method 
The percentage label claim present in Capsule formulation was found to be 
100.20% and 100.06% for Celecoxib and Diacerein respectively. The percentage 
recovery was found to be in the range of 99.97-100.90%. 
Area under curve 
The percentage label claim present in tablet formulation was found to be 100.48% 
and 100.08% for Celecoxib and Diacerein respectively.  The percentage recovery was 
found to be in the range of 100.71-100.16%. 
Derivative spectrophotometric method 
The percentage label claim present in tablet formulation was found to be 100.33% 
and 100.32% for Celecoxib and Diacerein respectively.  The percentage recovery was 
found to be in the range of 100.04-100.16%. 
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6.2 RP-HPLC method. 
RP-HPLC method has been developed for the estimation of both drugs in bulk 
and in formulation. The proposed method gives reliable assay results with short analysis 
time, using mobile phase Methanol: Water in the ratio of (85:15).  The contents of drug 
present in the formulation were found to be satisfactory and system suitability parameters 
are in desired limit. 
All the above methods do not suffer from any interference due to common 
excipients. It indicates that methods were accurate. Therefore the proposed methods 
could be successfully applied to estimate commercial pharmaceutical products containing 
Celecoxib and Diacerein 
Thus the above studies findings would be helpful to the analytical chemists to 
apply the analytical methods for the routine analysis of the analyte in pharmaceutical 
dosage forms after their approval from FDA. 
 
 
 
 
 
 
  
 
FIGURES 
FIGURE – 1 
IR SPECTRUM OF CELECOXIB 
 
 
FIGURE – 2 
IR SPECTRUM OF DIACEREIN 
 
FIGURE – 3  
UV SPECTRUM OF CELECOXIB AT  
1 mL DIMETHYL SULPHOXIDE AND METHANOL AT 251.5 nm  
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 FIGURE – 4 
UV SPECTRUM OF DIACEREIN AT  
1 mL DIMETHYL SULPHOXIDE AND METHANOL AT 258 nm  
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 FIGURE – 5 
UV OVERLAIND SPECTRUM OF CELECOXIB AND DIACEREIN IN  
1 mL DIMETHYL SULPHOXIDE AND METHANOL  
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FIGURE – 6 
CALIBRATION CURVE OF CELECOXIB IN  
1 ml DIMETHYL SULPHOXIDE AND METHANOL AT 236 nm 
 
(SIMULTANEOUS EQUATION METHOD) 
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FIGURE – 7 
CALIBRATION CURVE OF CELECOXIB IN  
1 mL DIMETHYL SULPHOXIDE AND METHANOL AT 269 nm 
 
(SIMULTANEOUS EQUATION METHOD) 
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FIGURE – 8 
CALIBRATION CURVE OF DIACEREIN IN  
1 mL DIMETHYL SULPHOXIDE AND METHANOL AT 236 nm 
 
(SIMULTANEOUS EQUATION METHOD) 
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FIGURE – 9 
CALIBRATION CURVE OF DIACEREIN IN  
1 mL DIMETHYL SULPHOXIDE AND METHANOL AT 269 nm 
 
(SIMULTANEOUS EQUATION METHOD) 
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FIGURE – 10 
CALIBRATION CURVE OF CELECOXIB IN  
1 mL DIMETHYL SULPHOXIDE AND METHANOL AT 236 - 246 nm 
 
(AREA UNDER CURVE) 
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FIGURE – 11 
CALIBRATION CURVE OF CELECOXIB IN  
1 mL DIMETHYL SULPHOXIDE AND METHANOL AT 267 - 273 nm 
 
(AREA UNDER CURVE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
0.5565
1.0632
1.5901
2.0989
2.6251
0
0.5
1
1.5
2
2.5
3
0 5 10 15 20 25
A
B
S
O
R
B
A
N
C
E
CONCENTRATION [µg/ mL]
FIGURE – 12 
CALIBRATION CURVE OF DIACEREIN IN  
1 mL DIMETHYL SULPHOXIDE AND METHANOL AT 236 - 246 nm 
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FIGURE – 13 
CALIBRATION CURVE OF DIACEREIN IN  
1 mL DIMETHYL SULPHOXIDE AND METHANOL AT 267 - 273 nm 
(AREA UNDER CURVE) 
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FIGURE – 14 
FIRST ORDER DERIVATIVE CURVE OF CELECOXIB AT 294 nm  
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FIGURE – 15 
FIRST ORDER DERIVATIVE CURVE OF DIACEREIN AT 245 nm  
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FIGURE – 16 
FIRST ORDER OVERLAID SPECTRUM OF CELECOXIB AND DIACEREIN  
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FIGURE – 17 
CALIBRATION CURVE OF CELECOXIB IN  
1 mL DIMETHYL SULPHOXIDE AND METHANOL AT 294 nm 
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FIGURE – 18 
CALIBRATION CURVE OF DIACEREIN IN  
1 mL DIMETHYL SULPHOXIDE AND METHANOL AT 245 nm 
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FIGURE – 19 
BASE LINE CHROMATOGRAM USING METHANOL: WATER (85:15) 
 
 
 
 
 
 
 
 
 
 FIGURE – 20 
INDIVIDUAL CHROMATOGRAM OF CELECOXIB USING 
METHANOL: WATER (85:15) 
 
 
 
 
 
 
 
 
 FIGURE – 21 
INDIVIDUAL CHROMATOGRAM OF DIACEREIN USING  
METHANOL: WATER (85:15) 
 
 
 
 
 
 
 
 
 FIGURE – 22 
LINEARTY CHROMATOGRAM OF CELECOXIB (70 mcg/mL) AND  
DIACEREIN (35 mcg/mL) USING METHANOL: WATER (85:15) 
 
 
 
 
 
 
 
 
 
 FIGURE – 23 
LINEARTY CHROMATOGRAM OF CELECOXIB (80 mcg/mL) AND  
DIACEREIN (40 mcg/mL) USING METHANOL: WATER (85:15) 
 
 
 
 
 
 
 
 FIGURE – 24 
LINEARTY CHROMATOGRAM OF CELECOXIB (90 mcg/mL) AND  
DIACEREIN (45 mcg/mL) USING METHANOL: WATER (85:15) 
 
 
 
 
 
 
 
 
 
 FIGURE – 25 
 
LINEARTY CHROMATOGRAM OF CELECOXIB (100 mcg/mL) AND  
DIACEREIN (50 mcg/mL) USING METHANOL: WATER (85:15) 
 
 
 
 
 
 
 FIGURE – 26 
 
LINEARTY CHROMATOGRAM OF CELECOXIB (110 mcg/mL) AND  
DIACEREIN (55 mcg/mL) USING METHANOL: WATER (85:15) 
 
 
 
 
 
 FIGURE – 27 
 
LINEARTY CHROMATOGRAM OF CELECOXIB (120 mcg/mL) AND  
DIACEREIN (60 mcg/mL) USING METHANOL: WATER (85:15) 
 
 
 
 
 
 FIGURE – 28 
 
LINEARTY CHROMATOGRAM OF CELECOXIB (130 mcg/mL) AND  
DIACEREIN (65 mcg/mL) USING METHANOL: WATER (85:15) 
 
 
 
 
 
 FIGURE – 29 
CALIBRATION CURVE OF CELECOXIB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 FIGURE – 30 
 
CALIBRATION CURVE OF DIACEREIN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE – 31 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION (OSTIGARD®) IN 
LOW LEVEL CONCENTRATION-80% (1) 
 
 
                                                     
 
 
                                                        FIGURE –32 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION 
(OSTIGARD®) IN LOW LEVEL CONCENTRATION-80% (2) 
 
 
 
 
 FIGURE – 33 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION 
(OSTIGARD®) IN LOW LEVEL CONCENTRATION-80% (3) 
 
 
  
 
 
                                                               FIGURE – 34                                     
CHROMATOGRAM FOR ANALYSIS OF FORMULATION (OSTIGARD®) IN 
MID LEVEL CONCENTRATION-100% (1) 
 
 
 
 
 
 
 FIGURE – 35 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION 
(OSTIGARD® IN MID LEVEL CONCENTRATION-100% (2) 
 
 
 
 
FIGURE – 36 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION 
(OSTIGARD®) IN MID LEVEL CONCENTRATION-100% (3) 
 
 
 
 
 
FIGURE – 37 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION 
(OSTIGARD®) IN HIGH LEVEL CONCENTRATION-120% (1) 
 
 
 
 
 FIGURE – 38 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION 
(OSTIGARD®) IN HIGH LEVEL CONCENTRATION-120% (2) 
 
 
 
 
 FIGURE – 39 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION 
(OSTIGARD®) IN HIGH LEVEL CONCENTRATION-120% (3) 
 
 
 
 
FIGURE – 40 
CHROMATOGRAM FOR 110% RECOVERY OF FORMULATION 
(OSTIGARD®)  
   
 
FIGURE – 41 
CHROMATOGRAM FOR 120% RECOVERY OF FORMULATION 
(OSTIGARD®)  
 
 
 
 
 
 
 
 
 
 FIGURE – 42 
CHROMATOGRAM FOR 130% RECOVERY OF FORMULATION 
(OSTIGARD®)  
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TABLE-1 
 
SOLUBILITY PROFILE OF CELECOXIB AND DIACEREIN 
 
S. No. SOLVENTS CELECOXIB DIACEREIN 
1. Acetonitrile Soluble Slightly Soluble 
2. Acetone Soluble Slightly Soluble 
3. Butanol Soluble Very slightly soluble 
4. Benzene  Soluble Very slightly soluble 
5. Carbon tetra chloride  Soluble Very slightly soluble 
6. Chloroform Soluble Slightly Soluble 
7. Dimethyl formamide Soluble Sparingly Soluble 
8. 
Dimeththylsulphoxide 
(DMSO) 
Soluble Soluble 
9. Distilled water Insoluble Insoluble 
10. Ethanol Soluble Slightly Soluble 
11. Ethyl acetate Soluble Soluble 
12. HCl (0.1 N) Soluble Insoluble 
13. Methanol Soluble Slightly Soluble 
14. NaOH (0.1 N) In Soluble Sparingly Insoluble 
15. Toluene  Soluble Very slightly soluble 
 
 
 
 
 
 
 
 
 
 
  
TABLE-2 
 
OPTICAL PARAMETERS OF CELECOXIB AND DIACEREIN BY 
SIMULTANEOUS EQUATION METHOD 
 
 
PARAMETERS CELECOXIB DIACEREIN 
max(nm) 236 269 
Beers law limit (g/ mL) 4-20 2-10 
Sandell’s sensitivity (g/cm2/0.001 
A.U) 
0.032816 0.025325 
Molar absorptivity (L mol
–1 
cm
–1
) 16918.74
 
14276.72
 
Correlation coefficient (r) 0.99996 0.99997 
Regression equation (y = mx + c) Y = 0.062922 X + 0.00381 Y = 0.038448 X + 0.002269 
Slope(m) 0.062922 0.038448 
Intercept(c) 0.00381 0.002269 
LOD (g /mL) 0.091034519 0.0034165157 
LOQ (g/ mL) 0.275862176 0.103530778 
Standard error of mean of Regression 
line 
0.000278 0.000095918 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
TABLE-3 
 
ASSAY OF COMMERCIAL FORMULATION BY UV- SPECTROSCOPY 
(SIMULTANEOUS EQUATION METHOD) 
 
* Mean of six Observations 
 
 
 
 
 
                            
 
 
 
 
 
Formulation Drug S. No 
Labelled 
amount 
(mg/tab)* 
Amount 
found 
(mg)* 
Percentage 
obtained* 
Average S.D. % RSD S.E 
OSTIGARD® 
100 
CEL 
1 100 100.41 100.41 
100.20 0.298 0.298 0.0083 
2 100 100.28 100.28 
3 100 100.51 100.51 
4 100 100.25 100.25 
5 100 99.66 99.66 
6 100 100.12 100.12 
DIA 
1 50 49.75 99.51 
100.06 0.629 0.628 0.0174 
2 50 49.94 99.88 
3 50 49.71 99.43 
4 50 49.95 99.91 
5 50 50.58 101.17 
6 50 50.07 100.15 
  
TABLE- 4 
INTRA DAY AND INTER DAY ANALYSIS OF FORMULATION  
(OSTIGARD®) BY SIMULTANEOUS EQUATION METHOD  
 
Drug 
Sample 
No. 
Labelled 
amount 
(mg/tab) 
Percentage 
obtained* 
S.D % R.S.D. S.E 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
CEL 
1 
2 
3 
4 
5 
6 
100 
100 
100 
100 
100 
100 
100.35 
100.31 
99.78 
99.75 
99.79 
99.80 
100.13 
100.31 
99.68 
99.75 
99.79 
99.80 
0.2847 0.2503 0.2848 0.2505 0.0079 0.0069 
Mean 99.96 99.91  
DIA 
1 
2 
3 
4 
5 
6 
50 
50 
50 
50 
50 
50 
99.64 
99.75 
100.88 
100.97 
100.86 
100.84 
100.11 
99.75 
101.16 
100.97 
100.86 
100.84 
0.61838 0.5544 0.6153 0.5510 0.0171 0.0196 
Mean 100.49 100.61  
 
* Mean of six Observations 
 
 
  
TABLE - 5 
RUGGEDNESS STUDY (OSTIGARD®) 
  
Drug Condition 
Average* 
% Obtained 
S.D 
% 
R.S.D 
S.E. 
CEL 
Analyst 1 
Analyst 2 
100.25 
100.28 
0.0212 0.0212 0.0053 
DIA 
Analyst 1 
Analyst 2 
99.88 
99.91 
0.0212 0.0212 0.005 
 
* Mean of Three Observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table - 6 
RECOVERY STUDY DATA OF 50 % PREANALYZED FORMULATION 
(OSTIGARD®) 
  
Drug 
Percentage 
Amount 
present* 
(mcg/mL) 
Amount 
added 
(mcg/mL) 
Amount 
estimated* 
(mcg/mL) 
Amount 
recovered* 
(mcg/mL) 
% Recovery* S.D 
% 
R.S.D 
S.E. 
CEL 
80 
100 
120 
8 
8 
8 
6.4 
8 
9.6 
14.4207 
15.9966 
17.5663 
6.4207 
7.9954 
9.5663 
100.33 
99.94 
99.64 
0.6638 
0.4951 
0.0251 
0.6609 
0.4954 
0.0252 
0.0736 
0.01212 
0.0027 
DIA 
80 
100 
120 
4 
4 
4 
3.2 
4 
4.8 
7.4076 
8.0384 
8.8719 
3.2075 
4.0384 
4.8729 
100.23 
100.96 
101.51 
1.4046 
1.1871 
0.5322 
1.4013 
1.1755 
0.5360 
0.1560 
0.1319 
0.05914 
 
* Mean of Three Observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TABLE-7 
OPTICAL PARAMETERS OF CELECOXIB AND DIACEREIN BY 
AREA UNDER CURVE METHOD 
 
PARAMETERS CELECOXIB DIACEREIN 
max(nm) 236-246 267-273 
Beers law limit (g/mL) 4-20 2-10 
Sandell’s sensitivity (g/cm2/0.001 
A.U) 
0.002909 0.002515 
Molar absorptivity (L mol
–1 
cm
–1
) 134462.3
 
146866.3
 
Correlation coefficient (r) 0.9999 0.9999 
Regressionequation (y = mx + c) Y = 0.343758 X + 0.088159 Y = 0.39759X + 0.011842 
Slope(m) 0.343758 0.39759 
Intercept(c) 0.088159 0.011842 
LOD (g/ mL) 0.057691092 0.003614595 
LOQ (g/ mL) 0.17482149 0.010953318 
Standard error of mean of 
Regression line 
0.001008 0.000752 
 
 
 
 
 
 
 
 
 
 
 
 
 TABLE-8 
ASSAY OF COMMERCIAL FORMULATION BY UV- SPECTROSCOPY 
(AREA UNDER CURVE METHOD) 
 
 
* Mean of six observations 
 
 
 
 
 
 
 
 
 
 
 
Formulation Drug S.No 
Labelled 
amount 
(mg/tab)* 
Amount 
found 
(mg)* 
Percentage 
obtained* 
Average S.D. % RSD S.E 
OSTIGARD® 
100 
CEL 
1 100 100.49 100.49 
100.48 0.2937 0.2923 0.00815 
2 100 100.99 100.99 
3 100 100.30 100.30 
4 100 100.61 100.61 
5 100 100.18 100.18 
6 100 100.30 100.30 
DIA 
1 50 50.03 100.07 
100.08 0.19935 0.19918 0.005537 
2 50 49.86 99.73 
3 50 50.10 100.20 
4 50 49.99 99.99 
5 50 50.14 100.28 
6 50 50.10 100.20 
 TABLE- 9 
 
INTRA DAY AND INTER DAY ANALYSIS OF FORMULATION BY 
(OSTIGARD®) AREA UNDER CURVE METHOD 
 
 
Drug 
Sample 
No. 
Labelled 
amount 
(mg/tab) 
Percentage 
obtained* 
S.D % R.S.D. S.E 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
CEL 
1 
2 
3 
100 
100 
100 
100.47 
100.43 
100.52 
100.55 
100.52 
100.55 
0.0450 0.0173 0.0448 0.0172 0.0050 0.0019 
Mean 100.47 100.54  
DIA 
1 
2 
3 
50 
50 
50 
100.09 
100.11 
100.05 
100.03 
100.05 
100.03 
0.0305 0.0115 0.0305 0.0115 0.0033 0.0012 
Mean 100.08 100.03  
 
 
* Mean of Three Observations 
 
 
 
 
 
 
 
 
 
 
 
 
 TABLE -10 
RUGGEDNESS STUDY BY (OSTIGARD®) AREA UNDER CURVE METHOD  
 
 
Drug Condition 
Percentage 
obtained 
1 
Percentage 
obtained 
2 
Percentage 
obtained 
3 
Average 
% 
S.D 
% 
R.S.D 
S.E. 
CEL 
Analyst 1 
Analyst 2 
100.65 
100.05 
100.48 
100.59 
100.24 
100.64 
100.45 
100.42 
0.2059 
0.3271 
0.2050 
0.3257 
0.0228 
0.0363 
DIA 
Analyst 1 
Analyst 2 
99.96 
100.01 
100.08 
100.06 
100.36 
99.26 
100.09 
100.01 
0.1404 
0.04509 
0.1403 
0.04508 
0.0156 
0.0050 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table - 11 
RECOVERY STUDY DATA OF 50 % PREANALYZED FORMULATION 
(OSTIGARD®) 
  
Drug 
Percentage 
Amount 
present* 
(mcg/mL) 
Amount 
added 
(mcg/mL) 
Amount 
estimated* 
(mcg/mL) 
Amount 
recovered* 
(mcg/mL) 
% Recovery* S.D 
% 
R.S.D 
S.E. 
CEL 
80 
100 
120 
8 
8 
8 
6.4 
8 
9.6 
14.4942 
16.0393 
17.7138 
    6.4942 
8.0393 
    9.7138 
101.47 
100.49 
101.18 
0.3291 
0.1522 
0.3291 
0.3257 
0.1512 
0.3257 
0.13438 
0.06214 
0.13418 
DIA 
80 
100 
120 
4 
4 
4 
3.2 
4 
4.8 
7.1977 
8.0196 
8.8806 
3.1977 
4.0196 
4.8060 
99.92 
100.44 
100.12 
0.2087 
0.3291 
0.2087 
0.2084 
0.3257 
0.2084 
0.0852 
0.13437 
0.08520 
 
 
* Mean of Three Observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE-12 
OPTICAL PARAMETERS OF CELECOXIB AND DIACEREIN BY 
FIRST ORDER DERIVATIVE METHOD 
 
 
PARAMETERS CELECOXIB DIACEREIN 
max(nm)       294      245 
Beers law limit (g/ mL)       4-20      2-10 
Sandell’s sensitivity (g/cm2/0.001 A.U)   1.41774  1.0574 
Molar absorptivity (L mol
–1 
cm
–1
)    267.915
 
   347.862
 
Correlation coefficient (r)     0.99995   0.99993 
Regressionequation (y = mx + c) Y = 0.00071X + 0.000029 Y = 0.00095X + 0.000012 
Slope(m) 0.00071 0.00095 
Intercept(c) 0.000029 0.000012 
LOD (g/ mL) 0.0141385 0.017553624 
LOQ (g/ mL) 0.042843941 0.0531928 
Standard error of mean of Regression 
line 
0.000056 0.000045 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE-13 
ASSAY OF COMMERCIAL FORMULATION BY UV- SPECTROSCOPY 
FIRST ORDER DERIVATIVE METHOD 
 
 
 
* Mean of six Observations 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation Drug S.No 
Labelled 
amount 
(mg/tab)* 
Amount 
found 
(mg)* 
Percentage 
obtained* 
Average S.D. % RSD S.E 
OSTIGARD® 
100 
CEL 
1 100 99.7468 99.7468 
100.33 0.915 0.9120 0.0254 
2 100 101.519 101.519 
3 100 101.519 101.51 
4 100 99.7468 99.74 
5 100 99.7468 99.74 
6 100 99.7468 99.74 
DIA 
1 50 50.3839 100.76 
100.32 1.079 1.075 0.0299 
2 50 50.3839 100.76 
3 50 50.3839 100.76 
4 50 49.6622 98.12 
5 50 50.3839 100.76 
6 50 50.3839 100.76 
TABLE- 14 
INTRA DAY AND INTER DAY ANALYSIS OF FORMULATION 
(OSTIGARD®) FIRST ORDER DERIVATIVE METHOD 
 
Drug 
Sample 
No. 
Labelled 
amount 
(mg/tab) 
Percentage 
obtained* 
S.D % R.S.D. S.E 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
CEL 
1 
2 
3 
100 
100 
100 
100.92 
100.33 
100.63 
100.33 
100.33 
100.63 
0.2950 0.1732 0.2931 0.1722 0.0081 0.0048 
Mean 100.62 100.43  
DIA 
1 
2 
3 
50 
50 
50 
99.88 
99.88 
99.44 
99.88 
100.32 
99.88 
0.2540 0.2540 0.2547 0.2539 0.0070 0.0070 
Mean 99.73 100.02 
 
 
 
 
* Mean of Three Observations 
 
 
 
 
 
  
TABLE -15 
RUGGEDNESS STUDY BY (OSTIGARD®) FIRST ORDER DERIVATIVE 
METHOD  
 
 
Drug Condition 
Percentage 
obtained 
1 
Percentage 
obtained 
2 
Percentage 
obtained 
3 
Average 
% 
S.D 
% 
R.S.D 
S.E. 
 
 
 
CEL 
 
 
 
Analyst 1 
 
Analyst 2 
 
 
 
 
100.70 
 
99.71 
 
 
 
99.49 
 
99.30 
 
 
 
99.30 
 
100.70 
 
 
 
99.83 
 
99.90 
 
 
0.7594 
 
 
0.7197 
 
 
0.7607 
 
0.7204 
 
 
0.0843 
 
 0.0799 
 
 
 
DIA 
 
 
 
 
Analyst 1 
 
Analyst 2 
 
. 
 
   100.41 
 
   101.07 
 
 
100.61 
 
98.12 
 
 
99.87 
 
100.76 
 
 
100.29 
 
99.98 
 
 
0.3827 
 
1.6211 
 
 
0.3816 
 
1.6213 
 
 
0.0156 
 
0.18012 
 
 
 
 
 
 
 
 
 
 
 
Table – 16 
 
RECOVERY STUDY DATA OF 50 % PREANALYZED FORMULATION 
(OSTIGARD®) 
  
Drug 
Percentage 
Amount 
present* 
(mcg/mL) 
Amount 
added 
(mcg/mL) 
Amount 
estimated* 
(mcg/mL) 
Amount 
recovered* 
(mcg/mL) 
% 
Recovery* 
S.D 
% 
R.S.D 
S.E. 
CEL 
80 
100 
120 
8 
8 
8 
6.4 
8 
9.6 
14.5013 
15.919 
17.4785 
6.5013 
7.919 
9.4785 
101.58 
98.98 
98.73 
0.4365 
0.3329 
0.1527 
0.4296 
0.3363 
0.1547 
0.04850 
0.03699 
0.01697 
DIA 
80 
100 
120 
4 
4 
4 
3.2 
4 
4.8 
7.2029 
8.0488 
8.8947 
3.2029 
4.0488 
4.8347 
100.09 
101.22 
100.72 
0.9200 
0.5900 
0.2730 
0.9191 
0.5828 
0.2710 
0.10222 
0.06550 
0.03033 
 
 
* Mean of Three Observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE - 17 
SYSTEM SUITABILITY PARAMETERS FOR THE OPTIMIZED 
CHROMATOGRAM BY RP - HPLC 
 
PARAMETERS CELECOXIB DIACEREIN 
Tailing factor 1.50 1.22 
Asymmetrical factor 1.58 1.26 
Theoretical plates 2965 1506 
Theoretical plate per unit 
Length 
197.66 100.40 
Resolution Between  DIA and CEL 7.15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE - 18 
OPTICAL CHARACTERISTICS OF CELECOXIB AND DIACEREIN BY  
RP - HPLC 
 
PARAMETERS CELECOXIB DIACEREIN 
max (nm) 252 252 
Beers law limit (μg/ mL) 70 -130 35 – 65 
Correlation coefficient (r) 0.9998 0.9996 
Regression equation (y=mx+c) y= 16649.2393x + 272062.6429 y=33258.0643 x + 68821.3571 
Slope (m) 272063 -68821 
Intercept (c) 16649 33258 
LOD (μg/ mL) 0.00025 0.0001606 
LOQ (μg/ mL) 0.00078 0.0004866 
Standard Error 0.15368 0.1143154 
 
 
 
 
 
 
 
 
 
 
 
 TABLE – 19 
QUANTIFICATION OF FORMULATION (OSTIGARD®) BY RP – HPLC 
 
Drug Conc. 
Sample 
No. 
Labelled 
amount 
(mg/tab) 
Amount 
found 
(mg) 
Percentage 
obtained 
Average ± S.D 
% 
R.S.D 
S.E. 
DIA 
Low 
level 
(80%) 
1 
2 
3 
100 
100 
100 
98.92 
98.84 
99.18 
98.92 
98.84 
99.18 
   99.14 0.1777 0.1795 0.0197 
Mid 
level 
(100%) 
1 
2 
3 
100 
100 
100 
98.84 
99.00 
98.68 
98.84 
99.00 
98.68 
98.84 0.1600 0.1618 0.0177 
High 
level 
(120%) 
1 
2 
3 
100 
100 
100 
99.00 
98.92 
98.95 
99.00 
98.92 
98.95 
98.95 0.0404 0.0408 0.0044 
ACE 
 
 
Low 
level 
(80%) 
1 
2 
3 
50 
50 
50 
49.90 
49.89 
49.95 
99.80 
99.79 
99.89 
   99.83 0.0550 0.0551 0.0061 
Mid 
level 
(100%) 
1 
2 
3 
50 
50 
50 
49.81 
49.97 
49.77 
99.62 
99.94 
99.54 
99.70 0.0529 0.0531 0.0058 
High 
level 
(120%) 
1 
2 
3 
50 
50 
50 
49.80 
49.95 
49.90 
99.60 
99.90 
99.81 
99.76 0.1539 0.1543 0.0171 
 
 
 
 
 
 
 
 
 TABLE – 20 
 
RECOVERY ANALYSIS OF FORMULATION (OSTIGARD®) BY RP - HPLC 
  
Drug Percentage 
Amount 
present* 
(mcg/mL) 
Amount 
added 
(mcg/mL) 
Amount 
estimated* 
(mcg/mL) 
Amount     
recovered* 
(mcg/mL) 
% 
Recovery* 
S.D 
% 
R.S.D 
S.E. 
CEL 
+10 spiked 
+20 spiked 
+30 spiked 
100 
100 
100 
10 
20 
30 
108.92 
118.95 
128.84 
9.947 
19.976 
29.858 
99.47 
99.88 
99.53 
0.2214 0.2222 0.02460 
DIA 
+10 spike 
+20 spike 
+30 spike 
50 
50 
50 
5 
10 
15 
54.86 
59.87 
64.89 
4.980 
9.992 
15.009 
99.61 
99.62 
100.06 
0.2569 0.2575 0.02855 
 
 
* Mean of Three Observations 
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